Advertisement
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1. Rossano MG, Schott HC, Kaneene JB, et al. Effect of daily administration of pyrantel tartrate in preventing infection in horses experimentally challenged with SarcocystiS neurona. Am J Vet Res 2005; 66:846–852.
-
2. Lindsay DS, Dubey JP. Determination of the activity of pyrantel tartrate against Sarcocystis neurona in γ-interferon gene knockout mice. Vet Parasitol 2001; 97:141–144.
-
3. Kruttlin EA, Rossano MG, Murphy AJ, et al. The effects of pyrantel tartrate on Sarcocystis neurona merozoite viability. Vet Ther 2001; 2:268–276.
-
4. Krungkrai J, Webster HK, Yuthavong Y. De novo and salvage biosynthesis of pteroylpentaglutamates in the human malaria parasite, Plasmodium falciparum. Mol Biochem Parasitol 1989; 32:25–37.
-
5. Kisthardt K, Lindsay DS. Equine protozoal myeloencephalitis. Equine Pract 1997; 19:8–13.
-
6. Lindsay SD, Dubey JP. Determination of activity of pyrimethamine, trimethoprim, sulfonamides, and combinations of pyrimethamine and sulfonomides against Sarcocystis neurona in cell cultures. Vet Parasitol 1999; 82:205–210.
-
7. Clarke CR, MacAllister CG, Burrows GE, et al. Pharmacokinetics, penetration into cerebrospinal fluid, and hematologic effects after multiple oral administrations of pyrimethamine to horses. Am J Vet Res 1992; 53:2296–2299.
-
8. Clarke CR, Burrows GE, MacAllister CG, et al. Pharmacokinetics of intravenously and orally administered pyrimethamine in horses. Am J Vet Res 1992; 53:2292–2295.
-
9. Brown MP, Kelly RH, Stover SM, et al. Trimethoprim-sulfadiazine in the horse: serum, synovial, peritoneal, and urine concentrations after single-dose intravenous administration. Am J Vet Res 1983; 44:540–543.
-
10. MacKay RL, Davis SW, Dubey JP. Equine protozoal myeloencephalitis. Compend Contin Educ Pract Vet 1992; 14:1359–1366.
-
11. Fenger CK, Granstrom DE, Langemeier JL, et al. Equine protozoal myeloencephalitis: findings from a retrospective study, in Proceedings. 42nd Annu Meet Am Assoc Equine Pract 1996; 80–81.
-
12. Reed SM, Saville WJ. Equine protozoal encephalomyelitis, in Proceedings. 42nd Annu Meet Am Assoc Equine Pract 1996; 75–79.
-
13. Welsch BB. Treatment of equine protozoal myeloencephalitis. Compend Contin Educ Pract Vet 1991; 13:1599–1602.
-
14. Toribio RE, Bain FT, Mrad DR, et al. Congenital defects in newborn foals of mares treated for equine protozoal myeloencephalitis during pregnancy. J Am Vet Med Assoc 1998; 212:697–701.
-
15. Bedford SJ, McDonnell SM. Measurements of reproductive function in stallions treated with trimethoprim-sulfamethoxazole and pyrimethamine. J Am Vet Med Assoc 1999; 215:1317–1319.
-
16. MacKay RJ. Equine protozoal myeloencephalitis. Vet Clin North Am Equine Pract 1997; 13:79–96.
-
17. Fleeger CA. USP dictionary of USAN and international drug names. Rockville, Md: US Pharmacopeia, 1997;227.
-
18. Vanparijs O, Hermans L, Marsboom R. Anticoccidial efficacy of diclazuril in pheasants. Vet Rec 1990; 126:332–333.
-
19. Alzieu JP, Mage C, Maes L, et al. Economic benefits of prophylaxis with diclazuril against subclinical coccidiosis in lambs reared indoors. Vet Rec 1999; 144:442–444.
-
20. Lindsay DS, Rippey SN, Toivio-Kinnucan MA, et al. Ultrastructural effects of diclazuril against Toxoplasma gondii and investigation of a diclazuril-resistant mutant. J Parasitol 1995; 81:459–466.
-
21. Lindsay DS, Blagburn LB. Activity of diclazuril against Toxoplasma gondii in cultured cells and mice. Am J Vet Res 1994; 55:530–533.
-
22. McDougald LR, Mathis GF, Seibert B. Anticoccidial efficacy of diclazuril against recent field isolates of Eimeria from commercial poultry farms. Avian Dis 1990; 34:911–915.
-
23. McDougald LR, Mathis GF, Seibert B. Anticoccidial efficacy of diclazuril against recent isolates of Eimeria from turkey farms in the United States. Avian Dis 1991; 35:863–868.
-
24. Vanparijs O, Hermans L, Marsboom R. Efficacy of diclazuril against turkey coccidiosis in a floor-pen experiment. Avian Dis 1989; 33:479–481.
-
25. Lindsay DS, Rippey SN, Blagburn LB. Treatment of acute Toxoplasma gondii infections in mice with diclazuril or a combination of diclazuril and pyrimethamine. J Parasitol 1995; 81:315–318.
-
26. Limson-Pobre RNR, Merrick S, Gruen D, et al. Use of dizlazuril for the treatment of isosporiasis in patients with AIDS. Clin Infect Dis 1995; 20:201–202.
-
27. Fung HB, Kirschenbaum HL. Treatment regimens for patients with toxoplasmic encephalitis. Clin Ther 1996; 18:1037–1056.
-
28. Menichetti F, Moretti MV, Marroni M, et al. Diclazuril for cryptosporidiosis in AIDS [lett]. Am J Med 1991; 90:271–272.
-
29. Kayembe K, Desmet P, Henry PC, et al. Diclazuril for Isospora belli infection in AIDS. Lancet 1989; 1:1397–1398.
-
30. Dubey JP, Fritz D, Lindsay DS, et al. Diclazuril preventive therapy of gamma interferon knockout mice fed Sarcocystis neurona sporocysts. Vet Parasitol 2001; 94:257–264.
-
31. Lindsay DS, Dubey JP. Determination of the activity of diclazuril against Sarcocystis neurona and Sarcocystis falcatula in cell cultures. J Parasitol 2000; 86:164–166.
-
32. Marsh AE, Mullins AL, Lakritz J. In vitro quantitative analysis of 3H-uracil incorporation by Sarcocystis neurona to determine efficacy of anti-protozoal agents. Vet Parasitol 2001; 95:241–249.
-
33. Peters JE, Geeroms R. Efficacy of toltrazuril against intestinal and hepatic coccidiosis in rabbits. Vet Parasitol 1986; 22:21–35.
-
34. Chapman HD. Control of a line of E. tenella, partly resistant to monensin, by including toltrazuril discontinuously in the drinking water of chickens. J Comp Pathol 1987; 97:21–27.
-
35. Reynaud MC, Chauve CM, Gastellu J, et al. Administration of toltrazuril during experimental coccidiosis in mule ducks: comparison of the efficacy of a single administration at two different endogenous stages. Vet Parasitol 1999; 81:265–274.
-
36. Vazquez F, Vazquez R. Toltrazuril: a new anticoccidial drug against all species of coccidian, in Proceedings. West Poult Dis Conf 1990; 39:74–76.
-
37. Lindsay SD, Dubey JP, Kennedy TJ. Determination of the activity of ponazuril against Sarcocystis neurona in cell cultures. Vet Parasitol 2000; 92:165–169.
-
38. Franklin RP, Mackay RJ, Gillis KD, et al. Effect of a single dose of ponazuril in neural infection and clinical disease in Sarcocystis neurona–challenged interferon-gamma knockout mice. Vet Parasitol 2003; 114:123–130.
-
39. Siddall ME. Hohlzylinders. Parasitol Today 1992; 8:90–91.
-
40. Kohler S, Delwiche CF, Denny PW, et al. A plastid of probable green algal origin in apicomplexan parasites. Science 1997; 275:1485–1489.
-
41. Hackstein JHP, Meijerink PPJ, Schubert H, et al. Parasitic apicomplexans harbor a chlorophyll a-D1 complex, the potential target for therapeutic triazines. Parasitol Res 1995; 81:207–216.
-
42. Wilson RJM, Denny PW, Preiser PR, et al. Complete gene map of the plastid-like DNA of the malaria parasite Plasmodium falciparum. J Mol Biol 1997; 261:155–172.
-
43. Jeffries AC, Johnson AM. The growing importance of the plastid-like DNAs of the Apicomplexa. Int J Parasitol 1996; 26:1139–1150.
-
44. Verheyen A, Maes L, Caussement W, et al. In vivo action of the anticoccidial diclazuril (Clinacox) on the development stages of Eimeria tenella: an ultrastructural evaluation. J Parasitol 1988; 74:939–949.
-
45. Mehlhorn H, Ortman-Falkenstein G, Haberkorn A. The effects of symmetrical triazinones on developmental stages of Eimeria tenella, E. maxima and E. acervulina: a light and electron microscopical study. Z Parasitenkd 1984; 70:173–182.
-
46. Mitchell SM, Zajac AM, Davis WL, et al. The effects of ponazuril on development of apicompexans in vitro. J Eukaryot Microbiol 2005; 52:231–235.
-
47. Jockel J, Wendt B, Loffler M. Structural and functional comparison of agents interfering with dihydroorotate, succinate, and NADH oxidation of rat liver mitochondria. Biochem Pharmacol 1998; 56:1053–1060.
-
48. Harder A, Haberkorn A. Possible mode of action of toltrazuril: studies on two Eimeria species, mammalian and Ascaris suum enzymes. Parasitol Res 1989; 76:8–12.
-
49. Loffler M, Becker C, Wegerle E, et al. Catalytic enzyme histochemistry and biochemical analysis of dihydroorotate dehydrogenase/oxidase and succinate dehydrogenase in mammalian tissues, cells and mitochondria. Histochem Cell Biol 1996; 105:119–128.
-
50. Granstrom DE, McCrillis S, Wulff-Strobel C, et al. A clinical report of diclazuril treatment for equine protozoal myeloencephalitis, in Proceedings. 43rd Annu Meet Am Assoc Equine Pract 1997; 13–14.
-
51. Dirikolu L, Bentz BG, Lehner AF, et al. New therapeutic approaches to equine protozoal myelo-encephalitis: pharmacokinetics of diclazuril sodium salts in the horse. Vet Ther 2006; 7:52–63.
-
52. Tobin T, Dirikolu L, Harkins JD, et al. Preliminary pharmacokinetics of diclazuril and toltrazuril in the horse, in Proceedings. 43rd Annu Meet Am Assoc Equine Pract 1997; 15–16.
-
53. Dirikolu L, Karpiesiuk W, Lehner AF, et al. Toltrazuril sulfone sodium salt: synthesis, analytical detection, and pharmacokinetics in the horse. J Vet Pharmacol Ther 2012; 35:265–274.
-
54. Dirikolu L, Karpiesiuk W, Lehner AF, et al. Synthesis and detection of toltrazuril sulfone and its pharmacokinetics in horses following administration in dimethylsulfoxide. J Vet Pharmacol Ther 2009; 32:368–378.
-
55. Dirikolu L, Woods WE, Carter W, et al. Diclazuril in the horse: its identification, detection and preliminary pharmacokinetics. J Vet Pharmacol Ther 1999; 22:374–379.
-
56. Furr M, Kennedy T. Cerebrospinal fluid and blood concentrations of toltrazuril 5% suspension in the horse after oral dosing. Vet Ther 2000; 1:125–132.
-
57. Furr M, Kennedy T. Cerebrospinal fluid and serum concentrations of ponazuril in horses. Vet Ther 2001; 2:232–237.
-
58. US FDA. Protazil antiprotozoal pellets. 1.56% diclazuril. Freedom of Information summary. Original new animal drug application. NADA 141-268. Available at: www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/ucm062320.pdf. Accessed Dec 1, 2011.
-
59. Benet LZ, Zia-Amirhosseini P. Basic principles of pharmacokinetics. Toxicol Pathol 1995; 23:115–123.
-
60. MacKay RJ, Granstrom DE, Saville WJ, et al. Equine protozoal myeloencephalitis (review). Vet Clin North Am Equine Pract 2000; 16:405–425.
-
61. Bentz BG, Dirikolu L, Carter WG, et al. Diclazuril and equine protozoal myeloencephalitis (EPM): a clinical report. Equine Vet Educ 2000; 2:258–263.
-
62. Furr M, Kennedy T, Mackay R, et al. Efficacy of ponazuril 15% oral paste as a treatment for equine protozoal myeloencephalitis. Vet Ther 2001; 2:215–222.
-
63. Kennedy T, Campbell J, Selzer V. Safety of ponazuril 15% oral paste in horses. Vet Ther 2001; 2:223–231.
-
64. Furr M, McKenzie H, Savile WJ, et al. Prophylactic administration of ponazuril reduces clinical signs and delays seroconversion in horses challenged with SarcocystiS neurona. J Parasitol 2006; 92:637–643.
-
65. MacKay RJ, Tanhauser ST, Gillis KD, et al. Effect of intermittent oral administration of ponazuril on experimental Sarcocystis neurona infection of horses. Am J Vet Res 2008; 69:396–402.
-
66. Dubreuil L, Houcke I, Mouton Y, et al. In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms. Antimicrob Agents Chemother 1996; 40:2266–2270.
-
67. Theodos CM, Griffiths JK, D'Onfro J, et al. Efficacy of nitazoxanide against Cryptosporidium parvum in cell culture and in animal models. Antimicrob Agents Chemother 1998; 42:1959–1965.
-
68. Megraud F, Occhialini A, Rossignol JF. Nitazoxanide, a potential drug for eradication of Helicopter pylori with no cross-resistance to metranidazole. Antimicrob Agents Chemother 1998; 42:2836–2840.
-
69. Rossignol JF, Maisonneuve H. Nitazoxanide in the treatment of Taenia saginata and Hymenolepis nana infections. Am J Trop Med Hyg 1984; 33:511–512.
-
70. Vatistas N, Fenger C, Palma K, et al. Initial experiences with the use of nitazoxanide in the treatment of equine protozoal encephalitis in northern California. Equine Pract 1999; 21:18–21.
-
71. Bentz BG, Granstrom DE, Stamper S. Seroprevalence of antibodies to Sarcocystis neurona in horses residing in a county of Southeastern Pennsylvania. J Am Vet Med Assoc 1997; 210:517–518.
-
72. Blythe LL, Granstrom DE, Hansen DE, et al. Seroprevalence of antibodies to Sarcocystis neurona in horses residing in Oregon. J Am Vet Med Assoc 1997; 210:525–527.
-
73. Rossano MG, Kaneene JB, Marteniuk JV, et al. The seroprevalence of antibodies to Sarcocystis neurona in Michigan equids. Prev Vet Med 2001; 48:113–128.
-
74. Saville WJ, Reed SM, Granstrom DE, et al. Seroprevalence of antibodies to Sarcocystis neurona in horses residing in Ohio. J Am Vet Med Assoc 1997; 210:519–524.
Advertisement
Current therapeutic approaches to equine protozoal myeloencephalitis
Contributor Notes
Supported in part by The National Horsemen's Benevolent and Protective Association; the Alabama, Arizona, Arkansas, Canada, Charles Town (West Virginia), Florida, Iowa, Indiana, Kentucky, Louisiana, Michigan, Minnesota, Nebraska, Ohio, Oklahoma, Ontario (Canada), Oregon, Pennsylvania, Tampa Bay Downs (Florida), Texas, Washington State, and West Virginia Horsemen's Benevolent and Protective Associations; the Florida Horsemen's Charitable Foundation; the Oklahoma Quarter Horse Racing Association; and Neogen Corp.
Powered by PubFactory